| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2547f03ae4cdc49b2e3fc719b877cb9e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_38ef360db79fced7e5f51b6ad097fe4a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_32da6a9278c5faa0058fbb29840fc609
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_87013d9ce73f879259a871945f232995
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_babb2bdb881da7bad5b25a12827a2619 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-8128
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-8125 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-81 |
| filingDate |
1995-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba12018101a70990f6a2f6b5c16d6dbe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_684c099ff444ec758edfe51b11330e69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_279f63070e80ab836932dd13fcdc7265
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_909dea35632b490ca8f01ec151ce4cc5 |
| publicationDate |
1996-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9610638-A1 |
| titleOfInvention |
Alpha-1-antitrypsin and antithrombine-iii variants |
| abstract |
Serine protease inhibitors (serpins) are provided which: (a) are substantially incapable of inhibiting activated protein C; (b) do not require activation by heparin; and (c) comprise a target sequence capable of interacting with the proteolytic active site of thrombin thereby to inhibit the proteolytic activity of thrombin. Preferred serpins are muteins or variants of α1-antitrypsin, modified by inclusion of a thrombin-specific target sequence derived from antithrombin-III (AT-III). Such serpins have the specificity and irreversibility of action of AT-III, but do not have to be co-administered with heparin. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7879803-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0952215-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9217027-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6528299-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0069256-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012004437-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6911334-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7510828-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6638909-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0952215-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2374054-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100776921-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8563693-B2 |
| priorityDate |
1994-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |